Arrowhead Pharmaceuticals' Dual-Gene RNAi Trial Marks New Era in Cardiometabolic Drug Research

Arrowhead Pharmaceuticals reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, a dual-gene RNAi drug candidate for atherosclerotic cardiovascular disease. This marks the first time a single RNA interference molecule has been advanced into human testing to target two genes simultaneously, highlighting Arrowhead's TRiM platform as an important platform-level development in cardiometabolic drug research. The launch of this trial strengthens Arrowhead's investment narrative around cardiometabolic innovation and platform potential.